Antifungal drugs are used to treat fungal infections in individuals. Common fungal infections such as fungal nail infection, and ringworm etc. usually occur on the external surface of the body, while certain invasive fungal infections occur inside the body tissues or inside internal organs such as lungs and brain. Fungal infection is usually associated with individuals having weak immune system, such as people suffering from HIV/AIDS. Moreover, patients undergoing chemotherapy are susceptible to invasive fungal infections. Antifungal drugs act against the fungal infections by either killing the fungal cells or by inhibiting their growth. Antifungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.
Market Dynamics
Major players in the market are focused on growth strategies such as collaborations and agreements in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered into an agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution rights of Beasilea’s antifungal treatments. Pfizer will manufacture and distribute drugs for the treatment of life-threatening invasive mold infections in regions like Russia, Israel, Europe (excluding Nordics), and Turkey.
Similarly, key players in the market are focused on various business strategies such as research and development in order to expand their product portfolio. Increasing drug development is expected to drive growth of this market. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from their first interim efficiency analysis of an ongoing FURI study. The development of this novel treatment is indicated for antifungal treatment.
Key features of the study:
- This report provides an in-depth analysis of global antifungal drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global antifungal drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global antifungal drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antifungal drugs market
Detailed Segmentation:
- Global Antifungal Drugs Market, By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- Global Antifungal Drugs Market, By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- Global Antifungal Drugs Market, By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- Global Antifungal Drugs Market, By Region:
- North America
- By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- By Country:
- Latin America
- By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type:
- Echinocandins
- Polyenes
- Allylamines
- Azoles
- Others
- By Indication:
- Aspergillosis
- Dermatophytosis
- Candidiasis
- Mucormycosis
- Others
- By Dosage Form:
- Powders
- Ointments
- Drugs
- Others
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- GlaxoSmithKline Plc *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bayer AG
- Abbott Laboratories
- Merck & Co., Inc
- Glenmark Pharmaceuticals Limited
- Enzon Pharmaceuticals, Inc.
- Pfizer Inc.
- Gilead Sciences, Inc.
- Sanofi S.A.
- Astellas Pharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
